Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer.

@article{Dotan2017PhaseIT,
  title={Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer.},
  author={Efrat Dotan and Steven A. Cohen and Alexander N. Starodub and Christopher Hanyoung Lieu and Wells A. Messersmith and Pamela S Simpson and Michael J Guarino and John Marshall and Richard M. Goldberg and Joel Randolph Hecht and William A. Wegener and Robert M Sharkey and Serengulam V. Govindan and David M. Goldenberg and Jordan D. Berlin},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2017},
  volume={35 29},
  pages={3338-3346}
}
Purpose The objectives were to evaluate dosing schedules of labetuzumab govitecan, an antibody-drug conjugate targeting carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) for tumor delivery of 7-ethyl-10-hydroxycamptothecin (SN-38), in an expanded phase II trial of patients with relapsed or refractory metastatic colorectal cancer. Patients and Methods Eligible patients with at least one prior irinotecan-containing therapy received labetuzumab govitecan once weekly at 8 and 10… CONTINUE READING